Medical Device Single Audit Program (MDSAP)

If you are a medical device manufacturer, take advantage of the MDSAP.

This unique program for Medical Devices allows you to apply for a single assessment of your quality management system (QMS) valid for all five participating countries: the United States, Canada, Brazil, Australia, and Japan.

researching by using microscope

The Certification Process

Preliminary phase
  • Gathering of information from the applicant manufacturer
  • Analysis of information in relation to the scope of GMED’s recognition
Initial certification audit
  • Initial audit preparation and planning
  • Audit
  • Issuance of interim report to the company
  • Submission of action plan by the company, if needed
  • Delivery of action plan analysis
  • Finalization of audit report and transmission to the company
Company monitoring
  • Surveillance audit: 1st year
  • Surveillance audit: 2nd year
Certification application
  • Proposal preparation and submission
  • Acceptance of proposal
  • Signing of contracts
Certification decision
  • Review of audit results
  • Decision
  • Communication of decision
  • Issuing of certificate(s), if audit results successful
  • Renewal audit: 3rd year

About the MDSAP program

1.What is the MDSAP program?

In 2012, the International Medical Device Regulators Forum (IMDRF) recognized the value in developing a global approach to auditing and monitoring medical device manufacturing in order to ensure medical device safety. A Medical Devices Single Audit Program was launched for the primary purpose of “jointly leveraging regulatory resources to manage an efficient, effective and sustainable single audit program focused on the oversight of medical device manufacturers.”

[International Medical Device Regulators Forum Medical Devices Single Audit Program, International Coalition Pilot Program sheet, January 2014]

When using the MDSAP, a medical device manufacturer enlists a recognized Auditing Organization (AO) to conduct the audit of its QMS based on the regulations of the five participating countries: Australia, Brazil, Canada, Japan, and the United States.

Under the MDSAP, the manufacturer’s quality management system undergoes a single assessment every year, with a full certification cycle of three years. This considerably reduces the number of audits and inspections that the medical device manufacturer must undergo with national regulators.

Each country decides how the MDSAP results apply in accordance with its laws. To date, the only country that has made the MDSAP mandatory is Canada, where it has been a requirement for class II, III, and IV medical devices (MDs) since January 1st, 2019.

The MDSAP audit results (audit report) are systematically uploaded to a database that can be accessed by all participating regulatory authorities.

2.What are the benefits of the MDSAP?

The MDSAP takes a global approach to quality management system audits and operates as an international coalition of countries dedicated to pooling resources, technologies, and services in order to improve safety and surveillance of medical devices around the world. The MDSAP is useful for medical device manufacturers who want to market their devices in the five countries that participate in the program.

MDSAP Benefits

  • Optimization of regulatory resources in one program to market your medical devices internationally in up to five countries: Japan, Brazil, Canada, Australia, and the United States;
  • ISO 13485:2016 certification for your company’s QMS compliance through the MDSAP;
  • Participation in an evolving international program, with 2 new affiliate members recently joining: South Korea and Argentina.
3.Is MDSAP mandatory?

The MDSAP is voluntary in Australia, Brazil, Japan, and the United States. However, it has been mandatory in Canada for class II, III, and IV medical devices since January 1st, 2019.


When manufacturers decide to participate in the MDSAP, they must list, in the certification contract, the countries where they are and/or will be marketing their medical devices. During the on-site audit, the manufacturer’s QMS compliance is reviewed against the national regulations of those countries

4.If the MDSAP becomes mandatory for one or more participating countries, do manufacturers have to comply with the regulations of a country where they do not market their products?

Medical device manufacturers must list the countries where they market their product in their certification contract.

[Medical Device Single Audit Program (MDSAP) Frequently Asked Questions, Version 016 of August 22,2017]

5.How are the MDSAP audit criteria related to the provisions of ISO 13485?

The MDSAP audit criteria include the provisions of ISO 13485, as well as the related requirements of participating regulatory authorities. In addition, other specific requirements from each regulatory authority may apply to products, licenses, company registrations, adverse event reports, etc.

An important provision for those implementing the MDSAP is that manufacturers may exclude the requirements of a country in which they have no intention to market medical devices. This means that the MDSAP audit criteria include ISO 13485 provisions and only the regulatory requirements that apply in the MDSAP countries where the company sells or intends to sell its product.

6.Can an MDSAP audit grant CE marking certification?

CE marking certification is independent from MDSAP certification. The European Union has an observer status and has no role in implementing the MDSAP. Both certification programs, however, can be conducted jointly.

7.What is an MDSAP affiliate member?

This special status, created in 2019, allows countries to use MDSAP certificates or audit reports to evaluate medical device manufacturers’ quality management systems within their own regulations.

As of the time of writing (March 2020), South Korea (Ministry of Food and Drug Safety) and Argentina (ANMAT) are the only affiliate members.

Accessing a five-country market

MDSAP Certification

Participating Countries

United States

The Food and Drug Administration (FDA)

The Center for Devices and Radiological Health (CDRH), a branch of the FDA, accepts MDSAP audit reports as a substitute for FDA routine inspections (every two years, according to established procedures).

[Medical Device Single Audit Program (MDSAP) Frequently Asked Questions, Version 016 of August 22, 2017]


  • Inspections conducted “For Cause” or as “Compliance Follow-up”;
  • Necessary pre-approval or post-approval inspections for Premarket Approval (PMA) applications; decisions under section 513(f)(5) of the Act (21 U.S.C. 360c(f)(5)) concerning the classification of a device;
  • Combination products.
Learn More
gmed assist

Choose GMED to take advantage of the MDSAP

  • GMED is recognized as an Auditing Organization by the MDSAP Regulatory Authority Council (RAC). It has participated in the program since it was launched by authorities, and has been conducting MDSAP audits since April 2015;
  • Not only does GMED have a solid reputation, but most of its auditors are qualified to conduct both Quality Management System audits (MDSAP and ISO) and regulatory audits (CE marking), an added benefit for medical device manufacturers wishing to combine their certification processes;
  • When you combine your certification processes, you can rest assured that GMED, as your Auditing Organization, will provide you with optimized planning, reducing the time your company’s resources have to devote to the audit cycle.


View all our technical, regulatory and normative information including guides, webinars, news…

Guidance MDCG 2022-16 on Authorized Representatives Regulation (EU) 2017/745 on medical...

The Medical Device Coordination Group (MDCG) has published the guidance MDCG 2022-16 for authorized representatives, manufacturers, and other economic operators. (...)

Learn more

Your certification projects for medical devices incorporating a medicinal substance under...

GMED has extensive experience with a team specialized in assessing medical devices incorporating medicinal substances under Regulation (EU) 2017/745 (analyzing (...)

Learn more

Current MHRA position regarding transitional requirements to the future regulation of...

On 21st October 2022, the Medicines & Healthcare products Regulatory Agency (MHRA) has just informed the industry stakeholders of a (...)

Learn more

Guidance MDCG 2022-15 on appropriate surveillance regarding the transitional provisions under...

The MDCG (Medical Devices Coordination Group) published the guidance MDCG 2022-15 on the appropriate surveillance to be conducted by Notified Bodies (...)

Learn more

In vitro diagnostic software: Novelties introduced by Regulation (EU) 2017/746

Regulation (EU) 2017/746 on in vitro diagnostic medical devices came into force on May 26, 2022. Among the novelties introduced (...)

Learn more

European Commission Newsletter on Medical Devices | September 2022

This newsletter from the European Commission aims to provide highlights and updates from the medical devices and in vitro diagnostic (...)

Learn more

Ava Sainter, IVD Product Reviewer, LNE-GMED UK

We are pleased to announce that Ava Sainter has joined our LNE-GMED UK subsidiary as an in vitro diagnostic (IVD) (...)

Learn more

Manual on borderline and classification for medical devices under Regulation (EU)...

The Borderline and Classification Working Group has just published on the European Commission website the Manual on borderline and classification (...)

Learn more


View all our technical, regulatory and normative information including guides, webinars, news…

Visit the Knowledge Center

Combining Certifications

Request for MDSAP Certification

With offices in Europe and North America, we serve the medical devices industry worldwide.